Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses.
Adult
Aged
Antibodies, Neutralizing
/ biosynthesis
Antibodies, Viral
/ biosynthesis
Betacoronavirus
/ immunology
CD4-Positive T-Lymphocytes
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
COVID-19
Convalescence
Coronavirus Infections
/ complications
Dendritic Cells
/ immunology
Diabetes Complications
Diabetes Mellitus
/ diagnosis
Disease Progression
Female
Humans
Hypertension
/ complications
Killer Cells, Natural
/ immunology
Lymphocyte Activation
Lymphocyte Count
Male
Middle Aged
Monocytes
/ immunology
Pandemics
Pneumonia, Viral
/ complications
SARS-CoV-2
Severity of Illness Index
COVID-19
SARS-CoV-2
T cell immune response
acute infection
convalescent
dendritic cell
neutralizing antibody
nucleocapsid protein
receptor-binding domain
Journal
Immunity
ISSN: 1097-4180
Titre abrégé: Immunity
Pays: United States
ID NLM: 9432918
Informations de publication
Date de publication:
13 10 2020
13 10 2020
Historique:
received:
19
05
2020
revised:
24
06
2020
accepted:
27
07
2020
pubmed:
14
8
2020
medline:
29
10
2020
entrez:
14
8
2020
Statut:
ppublish
Résumé
The SARS-CoV-2 pandemic has resulted in millions of infections, yet the role of host immune responses in early COVID-19 pathogenesis remains unclear. By investigating 17 acute and 24 convalescent patients, we found that acute SARS-CoV-2 infection resulted in broad immune cell reduction including T, natural killer, monocyte, and dendritic cells (DCs). DCs were significantly reduced with functional impairment, and ratios of conventional DCs to plasmacytoid DCs were increased among acute severe patients. Besides lymphocytopenia, although neutralizing antibodies were rapidly and abundantly generated in patients, there were delayed receptor binding domain (RBD)- and nucleocapsid protein (NP)-specific T cell responses during the first 3 weeks after symptoms onset. Moreover, acute RBD- and NP-specific T cell responses included relatively more CD4 T cells than CD8 T cells. Our findings provided evidence that impaired DCs, together with timely inverted strong antibody but weak CD8 T cell responses, could contribute to acute COVID-19 pathogenesis and have implications for vaccine development.
Identifiants
pubmed: 32791036
pii: S1074-7613(20)30333-2
doi: 10.1016/j.immuni.2020.07.026
pmc: PMC7402670
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
864-877.e5Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Interests The authors declare no competing interests.
Références
J Virol. 2004 Jun;78(11):5612-8
pubmed: 15140958
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
JCI Insight. 2019 Feb 21;4(4):
pubmed: 30830861
J Virol. 2020 Mar 17;94(7):
pubmed: 31996437
Emerg Infect Dis. 2005 Nov;11(11):1730-7
pubmed: 16318725
Immunity. 2020 Jun 16;52(6):971-977.e3
pubmed: 32413330
J Virol. 2010 Sep;84(18):9318-25
pubmed: 20610717
Zhonghua Yi Xue Za Zhi. 2004 Jan 2;84(1):22-6
pubmed: 14990151
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
J Clin Virol. 2020 Jun;127:104366
pubmed: 32302954
Lancet. 2020 May 30;395(10238):1695-1704
pubmed: 32401715
Emerg Microbes Infect. 2020 Dec;9(1):221-236
pubmed: 31987001
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Nat Med. 2020 Jun;26(6):842-844
pubmed: 32398875
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
J Med Virol. 2006 Jan;78(1):1-8
pubmed: 16299724
J Virol. 2005 Sep;79(18):11638-46
pubmed: 16140741
Emerg Infect Dis. 2005 Mar;11(3):411-6
pubmed: 15757556
BMC Immunol. 2009 Dec 03;10:61
pubmed: 19958537
J Immunol. 2005 Jun 15;174(12):7977-85
pubmed: 15944304
J Infect. 2020 Jul;81(1):e51-e60
pubmed: 32315725
J Exp Med. 2010 Jun 7;207(6):1247-60
pubmed: 20479116
N Engl J Med. 2020 Mar 5;382(10):929-936
pubmed: 32004427
Bioinformation. 2020 Mar 31;16(3):219-222
pubmed: 32308263
Clin Infect Dis. 2019 Mar 5;68(6):984-992
pubmed: 30060038
J Virol. 2014 Oct;88(19):11034-44
pubmed: 25056892
J Immunol. 2008 Oct 15;181(8):5490-500
pubmed: 18832706
Mucosal Immunol. 2016 Jul;9(4):1089-101
pubmed: 26647718
Nat Rev Immunol. 2004 Apr;4(4):308-12
pubmed: 15057789
Emerg Microbes Infect. 2020 Dec;9(1):1664-1670
pubmed: 32618497
J Clin Microbiol. 2020 Apr 23;58(5):
pubmed: 32132196
Nat Commun. 2020 Jul 14;11(1):3581
pubmed: 32665645
Blood. 2005 Oct 1;106(7):2366-74
pubmed: 15860669
J Infect. 2020 May;80(5):e1-e6
pubmed: 32171869
J Clin Invest. 2018 Jun 1;128(6):2239-2251
pubmed: 29461979
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Cell Host Microbe. 2020 Mar 11;27(3):325-328
pubmed: 32035028
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
J Immunol. 2004 Jul 15;173(2):1023-32
pubmed: 15240690
Cytokine Growth Factor Rev. 2008 Feb;19(1):3-19
pubmed: 18248767
J Exp Med. 2002 May 20;195(10):1279-88
pubmed: 12021308
J Immunol. 2005 Jul 1;175(1):591-8
pubmed: 15972696
Emerg Microbes Infect. 2020 Dec;9(1):2091-2093
pubmed: 32930052
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
Cell Mol Immunol. 2004 Apr;1(2):119-22
pubmed: 16212898
Clin Infect Dis. 2020 Sep 12;71(6):1400-1409
pubmed: 32270184
J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S3-23
pubmed: 20176265
J Immunol. 1998 Nov 15;161(10):5284-95
pubmed: 9820501
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
N Engl J Med. 2020 Mar 5;382(10):970-971
pubmed: 32003551
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Eur Respir J. 2020 May 7;55(5):
pubmed: 32269088